Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gary Schwartz, MD
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center; Lebanon, NH
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Ottawa, Ontario, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Minneapolis, Minnesota, United States
- Facility name not stated
Lebanon, New Hampshire, United States
- Facility name not stated
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2008
- Primary completion
- 31 Dec 2009
- Completion
- 31 Dec 2009
- Last update posted
- 29 Apr 2011
- Registered enrollment
- 19
- Registry id
- NCT00522457
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.